Long-term beta-blocker treatment prevents chronic creatine kinase and lactate dehydrogenase system changes in rat hearts after myocardial infarction

Wurzburg University, Germany.

OBJECTIVES. We tested the hypothesis that long-term beta-blocker treatment with bisoprolol prevents creatine kinase (CK) and lactate dehydrogenase system changes that occur after chronic myocardial infarction. BACKGROUND. The mechanism of the beneficial effect of beta-blocker therapy is still unclear. METHODS. Six groups of rats were studied. Sham operated (sham) and hearts with ligated left anterior descending coronary artery (myocardial infarction) were untreated, treated early (beginning 30 min after infarction) or treated late (beginning 14 days after infarction). After 8 weeks, hearts were isolated and buffer perfused isovolumetrically. With a left ventricular balloon, mechanical function was recorded at an end-diastolic pressure of 10 mm Hg. Biopsy samples of noninfarcted left ventricular tissue were taken. Enzyme activities were measured spectrophotometrically; isoenzymes were separated by agar gel electrophoresis; and total creatine levels were measured with high performance liquid chromatography. RESULTS. The decrease in left ventricular developed pressure in untreated hearts (120 +/- 9 vs. 104 +/- 5 mm Hg [mean +/- SE], p < 0.05, sham vs. myocardial infarction) after myocardial infarction was prevented by early treatment (118 +/- 9 vs. 113 +/- 4 mm Hg). Late treatment failed to improve mechanical function. Reduction of CK activity occurring in untreated infarcted hearts (6.4 +/- 0.3 vs. 5.1 +/- 0.3 IU/mg protein, p < 0.05, sham vs. myocardial infarction) was prevented by early beta-blocker therapy. The increase in CK isoenzyme BB and MB levels, decrease in mitochondrial CK isoenzyme levels and increase in anaerobic lactate dehydrogenase isoenzyme levels in untreated infarcted hearts did not occur during bisoprolol treatment. The decrease in total creatine levels after myocardial infarction (74.2 +/- 4.9 vs. 54.9 +/- 3.3 nmol/mg protein, p < 0.05, sham vs. myocardial infarction) was prevented by bisoprolol treatment. Early treatment was more effective than late therapy in preventing CK and lactate dehydrogenase system changes. In addition, in sham hearts, a 40% increase of creatine levels above normal levels was detected. CONCLUSIONS. Bisoprolol prevented changes in CK and lactate dehydrogenase system that occur after myocardial infarction. These observations may be related to the beneficial effects of long-term beta-blocker treatment in patients with chronic myocardial infarction.

This article has been cited by other articles:

				G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]

				K. Hu, A. Naumann, D. Fraccarollo, P. Gaudron, J. J. Kaden, S. Neubauer, and G. Ertl Heart rate reduction by zatebradine reduces infarct size and mortality but promotes remodeling in rats with experimental myocardial infarction Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1281 - H1288. [Abstract] [Full Text] [PDF]

				E. Omerovic, E. Bollano, B. Soussi, and F. Waagstein Selective {beta}1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure Eur J Heart Fail, December 1, 2003; 5(6): 725 - 732. [Abstract] [Full Text] [PDF]

				K.-D. Wagner, V. Essmann, K. Mydlak, M. Wirth, G. Gmehling, J. Bohlender, H. M. Stauss, J. Gunther, I. Schimke, and H. Scholz Decreased susceptibility of cardiac function to hypoxia-reoxygenation in renin-angiotensinogen transgenic rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R153 - R160. [Abstract] [Full Text] [PDF]

				H. Han, S. Hoffmann, K. Hu, and G. Ertl Angiotensin II subtype 1 (AT1) receptors contribute to ischemic contracture and regulate chemomechanical energy transduction in isolated transgenic rat ({alpha}MHC-hAT1)594-17 hearts Eur J Heart Fail, March 1, 2002; 4(2): 131 - 137. [Abstract] [Full Text] [PDF]

				F. Muders, S. Neubauer, A. Luchner, S. Fredersdorf, G. Ickenstein, G. A.J. Riegger, M. Horn, and D. Elsner Alterations in myocardial creatinine kinase (CK) and lactate dehydrogenase (LDH) isoenzyme-distribution in a model of left ventricular dysfunction Eur J Heart Fail, January 1, 2001; 3(1): 1 - 5. [Abstract] [Full Text] [PDF]

				E. Omerovic, E. Bollano, R. Mobini, V. Kujacic, B. Madhu, B. Soussi, M. Fu, A. Hjalmarson, F. Waagstein, and J. Isgaard Growth Hormone Improves Bioenergetics and Decreases Catecholamines in Postinfarct Rat Hearts Endocrinology, December 1, 2000; 141(12): 4592 - 4599. [Abstract] [Full Text] [PDF]

				S. Hugel, M. Horn, M. de Groot, H. Remkes, C. Dienesch, K. Hu, G. Ertl, and S. Neubauer Effects of ACE inhibition and beta -receptor blockade on energy metabolism in rats postmyocardial infarction Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2167 - H2175. [Abstract] [Full Text] [PDF]

				E. De Sousa, V. Veksler, A. Minajeva, A. Kaasik, P. Mateo, E. Mayoux, J. Hoerter, X. Bigard, B. Serrurier, and R. Ventura-Clapier Subcellular Creatine Kinase Alterations : Implications in Heart Failure Circ. Res., July 9, 1999; 85(1): 68 - 76. [Abstract] [Full Text] [PDF]

				M. Horn, H. Remkes, C. Dienesch, K. Hu, G. Ertl, and S. Neubauer Chronic high-dose creatine feeding does not attenuate left ventricular remodeling in rat hearts post-myocardial infarction Cardiovasc Res, July 1, 1999; 43(1): 117 - 124. [Abstract] [Full Text] [PDF]

				S. Neubauer, M. Horn, M. Cramer, K. Harre, J. B. Newell, W. Peters, T. Pabst, G. Ertl, D. Hahn, J. S. Ingwall, et al. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy Circulation, October 7, 1997; 96(7): 2190 - 2196. [Abstract] [Full Text]

				A. M. Persky and G. A. Brazeau Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate Pharmacol. Rev., June 1, 2001; 53(2): 161 - 176. [Abstract] [Full Text] [PDF]